The hypoglycemia-prevention effect of sensor-augmented pump therapy with predictive low glucose management in Japanese patients with type 1 diabetes mellitus: a short-term study

Published on Apr 9, 2020in Diabetology international
· DOI :10.1007/S13340-019-00408-7
Akihiro Katayama12
Estimated H-index: 12
(Okayama University),
Atsuhito Tone8
Estimated H-index: 8
+ 6 AuthorsJun Wada64
Estimated H-index: 64
(Okayama University)
Sources
Abstract
Aims/introduction The predictive low glucose management (PLGM) system was introduced in March 2018 in Japan. Although there are some reports demonstrating the benefit of PLGM in preventing hypoglycemia, no data are currently available in Japanese patients with type 1 diabetes mellitus (T1DM). The aim of the present study is to evaluate the effect of PLGM with sensor-augmented pump therapy in the prevention of hypoglycemia in Japanese patients.
📖 Papers frequently viewed together
References19
Newest
#1Emanuele Bosi (UniSR: Vita-Salute San Raffaele University)H-Index: 63
#2Pratik Choudhary (University of Cambridge)H-Index: 30
Last. Linda JamesH-Index: 1
view all 52 authors...
Summary Background Hypoglycaemia unawareness and severe hypoglycaemia can increase fear of hypoglycaemia and the risk of subsequent hypoglycaemic events. We aimed to assess the safety and efficacy of insulin pump therapy with integrated continuous glucose monitoring (CGM) and a suspend-before-low feature (Medtronic MiniMed 640G with SmartGuard) in hypoglycaemia-prone adults with type 1 diabetes. Methods SMILE was an open-label randomised controlled trial done in people aged 24–75 years with type...
Source
#1Valentino CherubiniH-Index: 23
#2Rosaria GesuitaH-Index: 24
Last. Andrea ScaramuzzaH-Index: 21
view all 22 authors...
OBJECTIVES: To assess the optimal setting of the predictive low glucose management (PLGM) algorithm for preventing exercise-induced hypoglycemia in adolescents with type 1 diabetes. METHODS: Thirty-four adolescents, 15 to 20 years, wearing PLGM system, were followed during 3 days exercise during a diabetes camp. PLGM threshold was set at 70 mg/dL between 8 am and 10 pm and 90 mg/dL during 10 pm and 8 am Adolescents were divided into group A and B, with PLGM threshold at 90 and 70 mg/dL, respecti...
Source
#1Lutz HeinemannH-Index: 76
#2Guido FreckmannH-Index: 26
Last. Norbert Hermanns (University of Bamberg)H-Index: 38
view all 7 authors...
Summary Background The effectiveness of real-time continuous glucose monitoring (rtCGM) in avoidance of hypoglycaemia among high-risk individuals with type 1 diabetes treated with multiple daily insulin injections (MDI) is unknown. We aimed to ascertain whether the incidence and severity of hypoglycaemia can be reduced through use of rtCGM in these individuals. Methods The HypoDE study was a 6-month, multicentre, open-label, parallel, randomised controlled trial done at 12 diabetes practices in ...
Source
#1Atsuko Matsuoka (Kobe University)H-Index: 3
#2Yushi Hirota (Kobe University)H-Index: 23
Last. Wataru Ogawa (Kobe University)H-Index: 61
view all 13 authors...
Aims Evidence suggests that sensor augmented pump (SAP) therapy is superior to conventional continuous subcutaneous insulin infusion (CSII) for achieving glycemic control in patients with type 1 diabetes. However, the clinical benefit of SAP therapy in East Asians has not yet been demonstrated.
Source
#1Mary B. Abraham (UWA: University of Western Australia)H-Index: 12
#2Jennifer A. Nicholas (UWA: University of Western Australia)H-Index: 8
Last. Timothy W. Jones (UWA: University of Western Australia)H-Index: 72
view all 9 authors...
OBJECTIVE Short-term studies with automated systems that suspend basal insulin when hypoglycemia is predicted have shown a reduction in hypoglycemia; however, efficacy and safety have not been established in long-term trials. RESEARCH DESIGN AND METHODS We conducted a 6-month, multicenter, randomized controlled trial in children and adolescents with type 1 diabetes using the Medtronic MiniMed 640G pump with Suspend before low (predictive low-glucose management [PLGM]) compared with sensor-augmen...
Source
#1Tadej Battelino (University of Ljubljana)H-Index: 54
#2Revital Nimri (SARA: San Antonio River Authority)H-Index: 23
Last. Natasa Bratina (Boston Children's Hospital)H-Index: 24
view all 5 authors...
OBJECTIVE To investigate whether predictive low-glucose management (PLGM) of the MiniMed 640G system significantly reduces the rate of hypoglycemia compared with sensor-augmented insulin pump in children with type 1 diabetes. RESEARCH DESIGN AND METHODS This randomized, two-arm, parallel, controlled, two-center open-label study included 100 children and adolescents with type 1 diabetes and glycated hemoglobin A 1c ≤10% (≤ 86 mmol/mol) and using continuous subcutaneous insulin infusion. Patients ...
Source
Abstract Background: A sensor-augmented insulin pump (SAP) using the MiniMed® 640G system with SmartGuard™ technology allows an automatic stop of insulin delivery based on prediction of low glucose levels. Since pediatric patients are particularly prone to hypoglycemia, this device may offer additional protection beyond conventional sensor-augmented therapy. Methods: This prospective, pediatric multicenter user evaluation assessed 6 weeks of SAP with SmartGuard (threshold setting for hypoglycemi...
Source
Importance Previous clinical trials showing the benefit of continuous glucose monitoring (CGM) in the management of type 1 diabetes predominantly have included adults using insulin pumps, even though the majority of adults with type 1 diabetes administer insulin by injection. Objective To determine the effectiveness of CGM in adults with type 1 diabetes treated with insulin injections. Design, Setting, and Participants Randomized clinical trial conducted between October 2014 and May 2016 at 24 e...
Source
#1Alex ZhongH-Index: 5
#2Pratik Choudhary ('KCL': King's College London)H-Index: 30
Last. Francine R. Kaufman (Medtronic plc)H-Index: 5
view all 7 authors...
Abstract Background: Automated insulin management features of the MiniMed® 640G sensor-augmented pump system include suspension in response to predicted low sensor glucose (SG) values (“suspend before low”), suspension in response to existing low SG values (“suspend on low”), and automatic restarting of basal insulin delivery upon SG recovery. The effectiveness of these features was evaluated using CareLink® software data. Methods: Anonymized data from MiniMed 640G system users (n = 4818), MiniM...
Source
#1Peter CalhounH-Index: 17
#2Bruce A. Buckingham (Stanford University)H-Index: 77
Last. John LumH-Index: 17
view all 12 authors...
Background:We developed a system to suspend insulin pump delivery overnight when the glucose trend predicts hypoglycemia. This predictive low-glucose suspend (PLGS) system substantially reduces nocturnal hypoglycemia without an increase in morning ketosis. Evaluation of hypoglycemia risk factors that could potentially influence the efficacy of the system remains critical for understanding possible problems with the system and identifying patients that may have the greatest benefit when using the...
Source
Cited By1
Newest
Abstract null null Aim null To analyse the real-life outcomes of two sensor-augmented pumps (SAP) with predictive low glucose suspend (PLGS) function, Medtronic Minimed 640G™ with SmartGuard (MM640G) and Tandem T Slim X2™ with Basal-IQ™ (TTSX2), in Type 1 Diabetes Mellitus (T1DM) patients. null null null Methods null Observational cross-sectional study using data obtained from computerized clinical records. All T1DM patients on TTSX2 therapy were compared (1:1) with MM640G treated patients selec...
Source
#1Hisae Honoki (University of Toyama)H-Index: 4
#2Kunimasa Yagi (University of Toyama)H-Index: 23
Last. Kazuyuki Tobe (University of Toyama)H-Index: 86
view all 15 authors...
Sensor-augmented insulin pump therapy with a predictive low glucose suspend (SAP-PLGS) feature is a remarkably progressed modality for the glycemic management of patients with type 1 diabetes. This technology avoids nocturnal hypoglycemia and severe hypoglycemia. A Brazilian woman developed type 1 diabetes at age 11 and was treated with multiple daily insulin injections. At age 20, she was admitted to our internal medicine department for her first pregnancy. Her HbA1c was 7.9% in the 6 weeks of ...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.